Market Capitalization

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

Eli Lilly's groundbreaking leukemia drug data signals a major market shift, promising better patient outcomes and fortifying its long-term growth strategy.

With its AI & Autonomy Day, Rivian is betting its future on software. Investors are watching to see if its tech can deliver a true competitive edge.

GoldMining Inc. renews its flexible financing tool to tap the market. We analyze the strategy, the projects at stake, and the dilution dilemma for investors.

Protara Therapeutics secured a $75M offering to advance its promising cancer drug, TARA-002, signaling renewed investor confidence in biotech innovation.

Global X's Bitcoin ETFs promise hefty semi-monthly payouts. But is this crypto-generated income a golden opportunity or a high-stakes volatility gamble?

How a Japanese labor firm is leveraging traditional osteopathy and high-profile sports events to execute an ambitious global expansion strategy.

A Swiss firm claims a CHF 480M raise and a $300M tech fund, but a closer look reveals a company with virtually no verifiable corporate footprint.

Alerus Financial’s 5% dividend increase isn’t just a payout; it’s a story of strategic diversification and resilience in a volatile banking sector.

Henri Beaufour’s passing transfers a major Ipsen stake to a charity. We analyze the governance safeguards and what it means when philanthropy enters the boardroom.

SoFi's surprise $1.5 billion stock sale sends shares tumbling. Is this a bold play for market dominance or a sign of fintech's increasing capital hunger?

A promising fintech's complex arbitrage strategy collapses, triggering a stock crash, CEO exit, and a wave of securities fraud investigations.

A regulatory filing shows hedge fund Balyasny's active trading in Avadel Pharma, exposing a merger arbitrage strategy amid a fierce bidding war.